Find a Tender
active
Official procurement procedure
The Development, Validation and Supply of Physostigmine Free Base
Design and execution of research and development
Medicinal products for the nervous system and sensory organs
Other nervous system medicinal products
+2 more
UK
Published value
£10,000,000
Submission deadline 28 Apr 2023, 17:00 BST
Lots published0
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Ministry of Defence, Defence Science and Technology Laboratory: "The Development, Validation and Supply of Physostigmine Free Base". Published status: active. Published value: £10,000,000. Lot information not published. Recorded submission deadline: 28 Apr 2023, 17:00 BST. See the official notice for participation instructions.
| Contracting Authority | Ministry of Defence, Defence Science and Technology Laboratory | Scope & Categories | Not published | Submission Window | Closed 28 Apr 2023, 17:00 BST |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £10,000,000 |
Bidder Intelligence · Authority Profile: Ministry of Defence, Defence Science and Technology Laboratory
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Ministry of Defence, Defence Science and Technology Laboratory. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
Not availableNo published reports
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 1 active published awards; 0 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityMinistry of Defence, Defence Science and Technology Laboratory | Procedure methodNot published | Procurement categoryNot published |
Statusactive | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published28 Mar 2023, 16:22 BST | Last source update28 Mar 2023, 16:22 BST | Recurring procurementNot published |
ClassificationDesign and execution of research and development, Medicinal products for the nervous system and sensory organs, Other nervous system medicinal products, Purchase, Various medicinal products | ||
Delivery area UK | ||
OCIDocds-h6vhtk-03b6c1 | ||
What is being bought
The Ministry of Defence (MoD) is inviting expressions of interest for a requirement for the provision of Physostigmine Free Base(also known as eserine; chemical name 1,2,3,3aβ,8,8aβ-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5-yl-methylcarbamate; chemical formula C15H21N3O2; molecular weight 275,36 g/mol). as part of an ongoing product development and anticipated commercialisation.
The initial Physostigmine supplied must be suitable for use in a pivotal Phase I clinical setting and the manufacturing process will produce material which does not add additional non-clinical activities to the overall programme, best endeavours should be taken to remove processing impurities.
The Supplier is to develop, scale-up and validate the manufacturing method for Physostigmine Free Base as an Active Pharmaceutical Ingredient (API) for use in a MoD final medicinal product currently under development.
The API must be developed and manufactured according to Good Manufacturing Practice (GMP) and must conform to European Transmissible Spongiform Encephalopathies (TSE) requirements, developed such that Intellectual property (IP) is vested in the Authority.
The Authority intends to seek a Marketing Authorisation for the final medicinal product from the Medicines and Healthcare products Regulatory Agency (MHRA) and Physostigmine will be required as an active ingredient for a future registered medicinal product.
The Supplier is required to provide information necessary for the Authority to complete the Chemistry, Manufacturing and Control (CMC) documentation to support a Clinical Trial Application (CTA) and Marketing Authorisation Application for the final medicinal product and make this documentation available to the MA applicant in an appropriate format for inclusion within CTD Module 3.
The Authority anticipates a Limited Quality by Design (QBD) approach to the manufacturing process as defined by the International Conference on Harmonisation (ICH).
All procurement documents are accessible via www.contracts.mod.uk Quantity or scope: The Contract has an expected duration of 10 years (120 months), plus 5 option years (60 months). Option years may be taken up consecutively or concurrently (to be determined).
What changed
From the official release history
- Published value updated to £10,000,000
28 Mar 2023, 16:22 BST - Status changed to active
28 Mar 2023, 16:22 BST - Official notice release published
28 Mar 2023, 16:22 BST - Submission deadline changed to 28 Apr 2023, 17:00 BST
28 Mar 2023, 16:22 BST - Buyer information updated
28 Mar 2023, 16:22 BST
Lots and requirements (0)
Published by the contracting authority
No lots are published for this procedure
Timeline
- Procedure published
28 Mar 2023, 16:22 BST - Submission deadline
28 Apr 2023, 17:00 BST
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
Ministry of Defence, Defence Science and Technology Laboratory
Contracting authority GB-FTS-77694Documents (1)
Official links; attachments are not copied
Related procedures (0)
No related procedures published